

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies (as amended)		

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the information listed on the Form PTO-1449 that accompanies this paper and the pending patent applications identified below. Applicant does not represent that a search has been conducted or that the cited documents are prior art against the claims in this application.

Copies of the cited non-U.S. patent documents, with the exception of items D62, D101, D153, D204, and D257 accompany this submission. The latter documents were submitted as attachments to the RCE and amendment filed on 7 August 2006 and are not duplicated here.

This disclosure statement is filed under the provisions of 37 C.F.R. § 1.97(b)(4) prior to the mailing date of an action on the merits following a Request for Continued Examination under 37 C.F.R. § 1.114. Applicant believes that no fee is due in connection with this disclosure statement. However, should any additional fee be required to render this paper timely or proper, applicant requests that the Director charge the required fee to our Deposit Account No. 18-1260.

Copending patent applications

In addition to the information cited on the Form PTO-1449 that accompanies this paper, applicant directs the examiner's attention to the commonly-owned pending U.S. patent applications listed below.

Serial No.	Filing Date	First Inventor
09/628,187	28 Jul 2000	White
09/762,587	06 Sep 2001	Grillo-López
09/911,692	25 Jul 2001	Anderson
09/911,703	25 Jul 2001	Anderson
10/096,964	14 Mar 2002	Anderson
10/196,732	17 Jul 2002	Grillo-López
10/238,681	11 Sep 2002	Anderson
10/440,186	19 May 2003	Grillo-López
10/850,712	21 May 2004	Grillo-López

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	D1	Re 38,008	25 Feb 2003	Abrams			
	D2	4,831,175	16 May 1989	Gansow			
	D3	4,975,278	4 Dec 1990	Senter			
	D4	5,099,069	24 Mar 1992	Gansow			
	D5	5,124,471	23 Jun 1992	Gansow			
	D6	5,246,692	21 Sep 1993	Gansow			
	D7	5,286,850	15 Feb 1994	Gansow			
	D8	5,439,665	8 Aug 1995	Hansen			
	D9	5,460,785	24 Oct 1995	Rhodes			
	D10	5,595,721	21 Jan 1997	Kaminski			
	D11	5,648,267	15 Jul 1997	Reff			
	D12	5,677,180	14 Oct 1997	Robinson			
	D13	5,686,072	11 Nov 1997	Uhr			
	D14	5,691,320	25 Nov 1997	van Borstel			
	D15	5,693,780	2 Dec 1997	Newman			
	D16	5,721,108	24 Feb 1998	Robinson			
	D17	5,726,023	10 Mar 1998	Cheever			
	D18	5,843,398	1 Dec 1998	Kaminski			
	D19	6,015,542	18 Jan 2000	Kaminski			
	D20	6,090,365	18 Jul 2000	Kaminski			
	D21	6,120,767	19 Sep 2000	Robinson			
	D22	6,287,537 B1	11 Sep 2001	Robinson			

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 1 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	D23	6,565,827 B1	20 May 2003	Kaminski			
	D24	6,652,852 B1	25 Nov 2003	Robinson			
	D25	6,893,625 B1	17 May 2005	Robinson			
	D26	2002/ 0009444 A1	24 Jan 2002	Grillo-López			
	D27	2002/ 0197255 A1	26 Dec 2002	Anderson			
	D28	2003/ 0021781 A1	30 Jan 2003	Anderson			
	D29	2003/ 0026804 A1	24 Feb 2003	Grillo-López			
	D30	2003/ 0082172 A1	1 May 2003	Anderson			
	D31	2003/ 0095963 A1	22 May 2003	Anderson			
	D32	2003/ 0206903 A1	6 Nov 2003	Grillo-López			
	D33	2004/ 0167319 A1	26 Aug 2004	Teeling			
	D34	2004/ 0213784 A1	28 Oct 2004	Grillo-López			
	D35	2004/ 056312 A2	8 Jul 2004	Adams			
	D36	2005/ 0163708 A1	28 July 2005	Robinson			
	D37	2005/ 0186205 A1	25 Aug 2005	Anderson			
	D38	2006/ 0034835 A1	16 Feb 2006	Adams			

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 2 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB.	TRANSLATION	
	D39	0 125 023 A1	14 Nov 1994	EP				
	D40	0 173 494 A2	5 May 1986	EP				
	D41	0 274 394 A2	13 Jul 1988	EP				
	D42	0 451 216 B1	24 Jan 1996	EP				
	D43	0 669 836 B1	7 Mar 1996	EP				
	D44	0 682 040 A1	15 Nov 1995	EP				
	D45	0 752 248 A1	8 Jan 1997	EP				
	D46	87/ 02671 A1	7 May 1987	WO				
	D47	88/ 04936 A1	14 Jul 1988	WO				
	D48	89/ 00999 A1	9 Feb 1989	WO				
	D49	91/ 04320 A1	4 Apr 1991	WO				
	D50	92/ 07466 A1	14 May 1992	WO				
	D51	93/ 02108 A1	4 Feb 1993	WO				
	D52	94/11026 A2	26 May 1994	WO				
	D53	00/ 09160 A1	24 Feb 2000	WO				
	D54	00/ 27428 A1	18 May 2000	WO				
	D55	00/ 27433 A1	18 May 2000	WO				
	D56	01/ 10460 A1	15 Feb 2001	WO				
	D57	2004/ 056312 A2	8 Jul 2004	WO				

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 3 OF 23

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	D58	Adams R.A. <i>Cancer Res.</i> 27: 2479-82, 1967. Formal discussion: the role of transplantation in the experimental investigation of human leukemia and lymphoma.
	D59	Adams R.A. et al. <i>Cancer Res.</i> 28(6): 1121-25, 1968. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2.
	D60	Alas S. et al. <i>Clin. Cancer Res.</i> 7(3): 709-23, 2001. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
	D61	Alas S. et al. <i>Clin. Cancer Res.</i> 8(3): 836-45, 2002. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
	D62	Almasri N.M. et al. <i>Am. J. Hematol.</i> 40: 259-63, 1992. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
	D63	Anderson D.R. et al. <i>Biochem. Soc. Trans.</i> 25(2): 705-08, 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
	D64	Anderson D.R. et al. Second IBC Int'l. Conference on Antibody Engineering, San Diego, 16-18 December 1991. Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody (abstract of presentation).
	D65	Anderson K.C. et al. <i>Blood</i> 63(6): 1424-33, 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.
	D66	Anderson K.C. et al. <i>Blood</i> 69(2): 597-604, 1987. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow.
	D67	Appelbaum F.R. <i>Hem. Onc. Clin. N. Amer.</i> 5(5): 1013-25, 1991. Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
	D68	Armitage J.O. et al. <i>Cancer</i> 50: 1695-1702, 1982. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D69	Armitage J.O. et al. <i>J. Clin. Oncol.</i> 16(8): 2780-95, 1998. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
	D70	Azogui O. et al. <i>J. Immunol.</i> 131: 1205-08, 1983. Inhibition of IL-2 production after human allogeneic bone marrow transplantation.
	D71	Badger C.C. et al. <i>Cancer Res.</i> 46: 6223-28, 1986. Experimental radioimmunotherapy of murine lymphoma with ¹³¹ I-labeled anti-T-cell antibodies.
	D72	Berinstein N.L. et al. <i>Ann. Oncol.</i> 9: 995-1001, 1998. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
	D73	Beychok S. (in) <i>Cells of Immunoglobulin Synthesis</i> , B. Pernis et al., eds. New York: Academic Press, 1979, 69-88. Comparative aspects of <i>in vitro</i> and cellular assembly of immunoglobulins.
	D74	Bhan A.K. et al. <i>J. Exp. Med.</i> 154: 737-49, 1981. Stages of B cell differentiation in human lymphoid tissue.
	D75	<i>Biogen Idec Inc. v. Corixa Corp.</i> , Case No. 01-CV-1637 IEG (RBB), Order Granting Patentees' Motion for Reconsideration, <i>etc.</i> (S.D.Cal., Jan. 22, 2004).
	D76	<i>Biogen Idec Inc. v. Corixa Corp.</i> , Case No. 01-CV-1637 IEG (RBB), Stipulation of Dismissal of Claims and Counterclaims with Prejudice and Order (S.D.Cal., May 13, 2004).
	D77	Bosly A. et al. <i>Nouv. Rev. Fr. Hematol.</i> 32(1): 13-16, 1990. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
	D78	Boulianne G.L. et al. <i>Nature</i> 312: 643-46, 1984. Production of functional chimaeric mouse/human antibody.
	D79	Brunner K.T. et al. <i>Immunology</i> 14(2): 181-96, 1968. Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹ Cr-labelled allogeneic target cells <i>in vitro</i> ; inhibition by isoantibody and by drugs.
	D80	Buchsbaum D.J. et al. <i>Cancer Res.</i> 50: 993s-999s, 1990. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D81	Buchsbaum D.J. et al. <i>Cancer Res.</i> 52: 637-642, 1992. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
	D82	Buchsbaum D.J. et al. <i>Cancer Res.</i> 52: 6476-81, 1992. Therapy with unlabeled and ¹³¹ I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
	D83	Buchsbaum D.J. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 18: 1033-41, 1990. A comparison of ¹³¹ I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.
	D84	Buchsbaum D.J. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 25(4): 629-38, 1993. Comparison of ¹³¹ I- and ⁹⁰ Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
	D85	Byrd J.C. et al. <i>Blood</i> 92(10 Suppl. 1): 106a, abst. no. 432, Nov. 1998. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid tumor lysis.
	D86	Byrd J.C. et al. <i>J. Clin. Oncol.</i> 19(8): 2153-64, 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
	D87	Caligiuri M.A. <i>Semin. Oncol.</i> 20(6 Suppl 9): 3-10, 1993. Low-dose interleukin-2 therapy: rationale and potential clinical applications.
	D88	Caligiuri M.A. et al. <i>J. Clin. Oncol.</i> 9(12): 2110-19, 1991. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
	D89	Caligiuri M.A. et al. <i>J. Clin. Invest.</i> 91(1): 123-32, 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
	D90	Calvert J.E. et al. <i>Semin. Hematol.</i> 21(4): 226-243, 1984. Cellular events in the differentiation of antibody-secreting cells.
	D91	Carrasquillo J.A. et al. <i>J. Nucl. Med.</i> 26: 67, abst. no. 276, 1985. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody.
	D92	Cayeux S. et al. <i>Blood</i> 74(6): 2270-77, 1989. T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogenous IL-2.
	D93	Chen J.J. et al. <i>J. Immunol.</i> 143(3): 1053-57, 1989. Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 6 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D94	Chinn P. et al. <i>Proc. Ann. Mtg. Am. Assn. Cancer Res.</i> 33: 337, abst. no. 2012, 1992. Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma.
	D95	Chinn P.C. et al. <i>Int. J. Oncol.</i> 15(5): 1017-25, Nov. 1999. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
	D96	Chinn P.C. et al. <i>Proc. Ann. Mtg. Am. Assn. Cancer Res.</i> 40: 574, abst. no. 3786, 1999. A ⁹⁰ Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium.
	D97	Chomczynski P. et al. <i>Anal. Biochem.</i> 162: 156-59, 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
	D98	Clark E.A. et al. <i>J. Cell. Biochem.</i> (Suppl. 9A): 63, 1985. Anti-Bp35 antibody induces human B cell proliferation: implications for <i>in vivo</i> immunotherapy.
	D99	Clark E.A. et al. <i>Proc. Natl. Acad. Sci. USA</i> 82(6): 1766-70, 1985. Role of the Bp35 cell surface polypeptide in human B-cell activation.
	D100	Classon B.J. et al. <i>J. Exp. Med.</i> 169(4): 1497-1502, 1989. The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OC-44 antigen.
	D101	Cogliatti S.B. et al. <i>Sw. Med. Weekly</i> 192: 607-17, 2002. Who is <i>WHO</i> and what was <i>REAL</i> ?
	D102	Cohen Y. et al. <i>Leuk. Lymphoma</i> 43(7): 1485-87, 2002. Large B-cell lymphoma manifesting as an invasive cardiac mass: sustained local remission after combination of methotrexate and rituximab.
	D103	Coiffier B. et al. <i>Blood</i> 92(6): 1927-32, 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
	D104	Coiffier B. et al. <i>N. Engl. J. Med.</i> 346(4): 235-42, 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
	D105	Coleman M. et al. <i>Blood</i> 102(11 pt.1): 29a, abst. no. 29, 2003. The BEXXAR® therapeutic regimen (tositumomab and Iodine I-131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naïve disease.
	D106	Colombat P. et al. <i>Blood</i> 97: 101-06, 2001. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
	D107	Cope. <i>Oncology</i> 8(4): 100, 1994. Antibody shows promise in treating B-cell lymphoma.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 7 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D108	Curti B.D. <i>Crit. Rev. Oncol. Hematol.</i> 14(1): 29-39, Feb. 1993. Physical barriers to drug delivery in tumors.
	D109	Czuczman M. et al. <i>Blood</i> 94(10 Suppl. 1): 99a, abst. no. 432, 1999. Rituximab/CHOP chemoimmunotherapy in patients (PTS) with low grade lymphoma (LG/F NHL): progression free survival (PFS) after three years (median) follow-up.
	D110	Czuczman M.S. et al. <i>J. Clin. Oncol.</i> 17(1): 268-76, Jan. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
	D111	Davis T. et al. <i>Blood</i> 90(10 Suppl. 1): 509a, abst. no. 2269 (Nov. 1997). Retreatments with RITUXAN™ (Rituximab, Idec-C2B8) have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL).
	D112	Davis T. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: abst. no. 39 (May 1998). Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with rituximab and alpha interferon: interim analysis.
	D113	Davis T.A. et al. <i>Blood</i> 86(10 Suppl. 1): 237a, abst. no. 1080, 1995. ⁹⁰ Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma.
	D114	Davis T.A. et al. <i>Blood</i> 92(10 Suppl. 1): 414a, abst. no. 1710, Nov. 1998. Rituximab: phase II (PII) retreatment (ReRx) study in patients (PTS) with low grade or follicular (LG/F) NHL.
	D115	Davis T.A. et al. <i>Blood</i> 92(10 Suppl. 1): 414a, abst. no. 1711, Nov. 1998. Rituximab: first report of a phase II (PII) trial in NHL patients (PTS) with bulky disease.
	D116	Davis T.A. et al. <i>Clin. Cancer Res.</i> 5(3): 611-15, 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
	D117	Davis T.A. et al. <i>J. Clin. Oncol.</i> 17(6): 1851-57, 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
	D118	Davis T.A. et al. <i>Proc. Ann. Mtg. Amer. Assn. Cancer Res.</i> 39: 435, abst. no. 2964, 1998. Therapy of B cell lymphoma with anti-CD20 can result in relapse with loss of CD20 expression.
	D119	Demidem A. et al. <i>Cancer Biother. Radiopharm.</i> 12(3): 177-86, 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
	D120	DeNardo G.L. et al. <i>Cancer Res.</i> 50(3 Suppl.): 1014s-1016s, 1990. Fractionated radioimmunotherapy of B-cell malignancies with ¹³¹ I-Lym-1.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 8 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D121	DeNardo G.L. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 11(2): 335-48, 1985. Requirements for a treatment plan in system for radioimmunotherapy.
	D122	DeNardo S.J. et al. <i>Antibody Immunoconj. Radiopharm.</i> 1(1): 17-33, 1988. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody.
	D123	DeNardo S.J. et al. <i>Cancer</i> 73(3 Suppl.): 1023-32, 1994. The biologic window for chimeric L6 radioimmunotherapy.
	D124	Di Gaetano N. et al. <i>Br. J. Haematol.</i> 114(4): 800-09, 2001. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
	D125	Dickson S. <i>Gen. Engr. News</i> 5(3): 1, March 1985. Scientists produce chimeric monoclonal Abs.
	D126	Dillman R.O. <i>J. Clin. Oncol.</i> 12(7): 1497-1515, 1994. Antibodies as cytotoxic therapy.
	D127	Eary J.F. et al. <i>J. Nuc. Med.</i> 31(8): 1257-68, 1990. Imaging and treatment of B-cell lymphoma.
	D128	Einfeld D.A. et al. <i>EMBO J.</i> 7: 711-17, 1988. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.
	D129	Endo K. <i>Jpn. J. Cancer Chemother.</i> 26: 744-48, 1999. Current status of nuclear medicine in Japan.
	D130	Flinn I.W. et al. <i>Blood</i> 92(10 Suppl. 1): 648a, abst. no. 2678, Nov. 1998. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL [sic].
	D131	Foran J.M. et al. <i>J. Clin. Oncol.</i> 18: 317-24, 2000. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
	D132	Freedman A.S. et al. <i>J. Clin. Oncol.</i> 8: 784-91, 1990. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
	D133	Friedberg J.W. et al. <i>Expert Rev. Anticancer Ther.</i> 4(1): 18-26, 2004. Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
	D134	Golay J.T. et al. <i>J. Immunol.</i> 135(6): 3795-801, 1985. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 9 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D135	Goldenberg D.M. et al. <i>J. Clin. Oncol.</i> 9(4): 548-64, 1991. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies.
	D136	Gordon L.I. et al. <i>Blood</i> 94(10 Suppl. 1): 91a, abst. no. 396, 1999. ZEVALIN™ (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL): interim results.
	D137	Gordon L.I. et al. <i>J. Immunother.</i> 22(5): 459, 1999. Update on IDEC-Y2B8 (ZEVALIN™) radioimmunotherapy of B-cell NHL.
	D138	Greenberger J.S. et al. <i>Cancer Res.</i> 45(2): 758-67, 1985. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
	D139	Greiner J.W. et al. <i>Science</i> 235(4791): 895-98, 1987. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.
	D140	Grillo-López A.J. IBC Int'l. Conference on Antibody Engineering, La Jolla, December 1994. IDEC-C2B8 chimeric antibody and IDEC-Y2B8 radiolabeled antibody phase I and II studies in patients with non-Hodgkin's lymphoma (abstract of presentation).
	D141	Grillo-López A.J. et al. <i>Ann. Oncol.</i> 7(3 Suppl.): 57, abst. no. 195, 1996. Treatment (rx) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-yttrium (90-Y) labeled anti-CD20 monoclonal antibody (MAB) IDEC-Y2B8: a phase I clinical trial (PI CT).
	D142	Grillo-López A.J. et al. <i>Antibody Immunoconj. Radiopharm.</i> 8: 60, abst. no. 10, 1995. Treatment options for patients with relapsed low-grade or follicular lymphoma: the role of IDEC-C2B8.
	D143	Grillo-López A.J. et al. <i>Blood</i> (86(10 Suppl. 1): 55a, abst. no. 207, 1995. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma.
	D144	Grillo-López A.J. et al. <i>Br. J. Haematol.</i> 93(Suppl. 2): 283, abst. no. 1072, 1996. IDEC-C2B8 chimeric anti-CD20 antibody (MAB): safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL).
	D145	Grossbard M.L. et al. <i>Blood</i> 80(4): 863-78, 1992. Monoclonal antibody-based therapies of leukemia and lymphoma.
	D146	Gura T. <i>Science</i> 278: 1041-42, 1997. Systems for identifying new drugs are often faulty.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D147	Hagenbeek A. et al. <i>J. Clin. Oncol.</i> 16(1): 41-47, 1998. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
	D148	Hainsworth J.D. et al. <i>Blood</i> 95: 3052-56, 2000. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.
	D149	Harris N.L. et al. <i>Blood</i> 54(5): 1361-92, 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
	D150	Harris N.L. et al. <i>J. Clin. Oncol.</i> 17(12): 3835-49, 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997.
	D151	Hartwell L.H. et al. <i>Science</i> 278: 1064-68, 1997. Integrating genetic approaches into the discovery of anticancer drugs.
	D152	Hekman A. et al. <i>Ann. Rept. Netherlands Cancer Inst., Amsterdam</i> , pages 47-48, 1993. Immunotherapy.
	D153	Herold M. et al. <i>Ann. Hematol.</i> 79: 332-335, 2000. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab.
	D154	Hiddemann W. et al. <i>Blood</i> 88(11): 4085-89, 1996. Lymphoma classification—the gap between biology and clinical management is closing.
	D155	Hooijberg E. et al. <i>Cancer Res.</i> 55: 2627-34, 1995. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
	D156	Horning S.J. et al. <i>Blood</i> 100(11 part 1): 357a, abst. no. 1385, 2002. Rituximab treatment failures: tositumomab and Iodine I 131 tositumomab (Bexxar®) can produce meaningful durable responses.
	D157	IDEC Pharmaceuticals Corp., U.S. Securities and Exchange Commission Form S-1 Registration Statement, 1991.
	D158	IDEC Pharmaceuticals Corp. and Genentech, Inc., Product insert for RITUXAN® approved by U.S. Food and Drug Administration on 26 November 1997.
	D159	International Non-Hodgkin's Lymphoma Prognostic Factors Project. <i>N. Engl. J. Med.</i> 329(14): 987-94, 1993. A predictive model for aggressive non-Hodgkin's lymphoma.
	D160	Jain R.K. <i>Sci. Am.</i> 271(1): 58-65, 1994. Barriers to drug delivery in solid tumors.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 11 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D161	Janakirman N. et al. <i>Blood</i> 92(10 Suppl. 1): 337a, abst. no. 1384, Nov. 1998. Rituximab: correlation between effector cells and clinical activity in NHL.
	D162	Juwaid M. et al. <i>Cancer Res.</i> 55(23 Suppl.): 5827s-5831s, 1995. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
	D163	Juwaid M. et al. <i>Cancer Res.</i> 55(23 Suppl.): 5899s-5907s, 1995. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
	D164	Kaminski M. et al. <i>Antibody Immunoconj. Radiopharm.</i> 4(1): 36, abst. no. 66, 1991. Phase I trial results of 131-I antibody radioimmunotherapy (RAIT) of B-cell lymphoma.
	D165	Kaminski M.S. et al. <i>Antibody Immunoconj. Radiopharm.</i> 5(3): 345, abst. no. 57, 1992. Initial clinical radioimmunotherapy results with ¹³¹ I-anti-B1 (anti-CD20) in refractory B-cell lymphoma."
	D166	Kaminski M.S. et al. <i>Blood</i> 76(10 Suppl. 1): 355a, abst. no. 1409, 1990. Phase I evaluation of 131-I MB-1 antibody radioimmunotherapy (RIT) of B-cell lymphoma.
	D167	Kaminski M.S. et al. <i>Blood</i> 78(10 Suppl. 1): 43a, abst. no. 161, 1992. Radioimmunotherapy (RIT) of refractory B-cell lymphoma with 131-I-anti-B1 (anti-CD20) antibody: promising early results using non-marrow ablative radiation doses.
	D168	Kaminski M.S. et al. <i>J Clin. Oncol.</i> 14(7): 1974-81, 1996. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
	D169	Kaminski M.S. et al. <i>N. Engl. J. Med.</i> 329: 459-65, 1993. Radioimmunotherapy of B-cell lymphoma with [¹³¹ I]anti-B1 (anti-CD20) antibody.
	D170	Kinoshita T. et al. <i>J. Clin. Oncol.</i> 16(12): 3916, Dec. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
	D171	Klarnet J.P. et al. <i>J. Immunol.</i> 138(11): 4012-17, 1987. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
	D172	Knox S.J. et al. <i>Clin. Cancer Res.</i> 2: 457-70, 1996. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
	D173	Knox S.J. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 32: 215, 1995. ⁹⁰ Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma.
	D174	Knox S.J. et al. <i>J. Immunother.</i> 16(2): 161, abst. no. 51, 1994. ⁹⁰ Y-anti-CD20 monoclonal antibody therapy (IDEC-Y2B8) for recurrent B cell lymphoma.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 12 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D175	Kuzel T. et al. <i>Cancer Biother.</i> 8(1): 3-16, 1993. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
	D176	Langmuir V.K. <i>Nucl. Med. Biol.</i> 19(2): 213-55, 1992. Radioimmunotherapy: clinical results and dosimetric considerations.
	D177	Larson S.M. et al. <i>Nucl. Med. Biol.</i> 16: 153-58, 1989. Comparison of bone marrow dosimetry and toxic effect of high dose ¹³¹ I-labeled monoclonal antibodies administered to man.
	D178	Lauria F. et al. <i>Bone Marrow Transplant.</i> 18(1): 79-85, 1996. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
	D179	Leichner P.K. et al. <i>Front. Rad. Ther. Oncol.</i> 24: 109-20, 1990. Dosimetry and treatment planning in radioimmunotherapy.
	D180	Leichner P.K. et al. <i>Med. Phys.</i> 20(2): 529-34, 1993. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.
	D181	Levy R. et al. <i>Fed. Proc.</i> 42: 2650-56, 1983. Tumor therapy with monoclonal antibodies.
	D182	Ling N.R. et al. (in) <i>Leucocyte Typing III: White Cell Differentiation Antigens</i> , A.J. McMichael et al., eds., Oxford: Oxford Univ. Pr., 1987, pp. 302-35. B-cell and plasma cell antigens: new and previously defined clusters.
	D183	Link B.K. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: 3a, abst. no. 7, 1998. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL.
	D184	Link M.P. et al. <i>J. Immunol.</i> 137(9): 3013-18, 1986. A unique antigen on mature B-cells defined by a monoclonal antibody.
	D185	Lipton J.M. et al. <i>Blood</i> 60(5 Suppl. 1): 170a, abst. no. 609, 1992. Distribution of B1, CALLA, β 2 microglobulin and Ia on hematopoiesis supporting cells (HSC) in short and long-term cultures.
	D186	Lonberg N. et al. <i>Nature</i> 368: 856-59, 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications
	D187	Lowman H.B. Slides presented at IBC Antibody Engineering Conference, 2 December 2003. Differential activities in a series of humanized anti-CD20 antibodies.
	D188	Lum L.G. et al. <i>Blood</i> 69(2): 369-80, 1987. The kinetics of immune reconstitution after human marrow transplantation.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 13 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D189	Macey D.J. et al. <i>Front. Rad. Ther. Oncol.</i> 24: 123-31, 1990. A treatment planning program for radioimmunotherapy.
	D190	Macklis R.M. et al. <i>Antibody Immunoconj. Radiother.</i> 5(3): abstr. no. 39, 1992. Induction of programmed cell death in malignant lymphomas after radioimmunotherapy.
	D191	Macklis R.M. et al. <i>Cancer</i> 73(3 Suppl.): 966-73, 1994. Radiobiologic studies of low-dose-rate ⁹⁰ Y-lymphoma therapy.
	D192	Maloney D.G. et al. <i>Blood</i> 80(6): 1502-1510, 1992. Monoclonal anti-idiotypic antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.
	D193	Maloney D.G. et al. <i>Blood</i> 88(10: Suppl. 1): 637a, abstr. no. 2635, 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.
	D194	Maloney D.M. et al. <i>Blood</i> 84(8): 2457-66, 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
	D195	Marquez S.D. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 39: 327, abstr. no. 2173, 1997. Hematological toxicity in radioimmunotherapy is predicted both by the computed absorbed whole body dose (cGy) and by the administered dose (mCi).
	D196	Marx J.L. <i>Science</i> 229(4712): 455-56, 1985. Antibodies made to order.
	D197	Masucci G. et al. <i>Med. Oncol. Tumor Pharmacother.</i> 8(3): 207-20, 1991. Chemotherapy and immunotherapy of colorectal cancer.
	D198	McLaughlin P. et al. <i>Blood</i> 92(10 Suppl. 1): 414a-415a, abstr. no. 1712, Nov. 1998. Efficacy controls and long-term follow-up for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
	D199	McLaughlin P. et al. <i>Oncology</i> 12(12): 1763-81, 1998. Clinical status and optimal use of rituximab for B-cell lymphomas.
	D200	Meredith R.F. et al. <i>J. Nucl. Med.</i> 33(9): 1648-53, 1992. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
	D201	Mishell B.E. et al., eds. <i>Selected Methods in Cellular Immunology</i> , San Francisco: Freeman (1980), p. 287-304. Modification and use of antibodies to label cell surface antigens.
	D202	Morrison S. et al. <i>Proc. Nat'l Acad. Sci. USA</i> 81: 6851-54, 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 14 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D203	Morrison S.L.. <i>Science</i> 229: 1202-07, 1985. Transfectomas provide novel chimeric antibodies.
	D204	Multani P.S. et al. <i>J. Clin. Oncol.</i> 16(11): 3691-3710, 1998. Monoclonal antibody-based therapies for hematologic malignancies.
	D205	Munro A. <i>Nature</i> 312: 597, 1984. Uses of chimeric antibodies.
	D206	Murray J.L. et al. <i>J. Biol. Resp. Modifiers</i> 9(6): 556-63, 1990. Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.
	D207	Murray J.L. et al. <i>J. Nucl. Med.</i> 26: 3328-29, 1985. The effect of radionuclide dose on imaging with indium-111-labeled anti P-97 monoclonal antibody.
	D208	Muzaffar S. et al. <i>J. Pak. Med. Assn.</i> 47(4): 106-09, April 1997. Immunophenotypic analysis of non-Hodgkin's lymphoma.
	D209	Nadler L.M. et al. <i>Cancer Res.</i> 40(9): 3147-54, 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.
	D210	Nadler L.M. et al. <i>J. Clin. Invest.</i> 67: 134-140, 1981. A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
	D211	Nadler L.M. et al. <i>J. Clin. Invest.</i> 74(2): 332-40, 1984. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.
	D212	Nadler L.M. et al. <i>Lancet</i> 2(8400): 427-31, 1984. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma.
	D213	Nakamura K. et al. <i>Oncology</i> 50(1): 35-40, 1993. Effect of alpha-interferon on anti-alpha fetoprotein-monooclonal-antibody targeting of hepatoma.
	D214	Neuberger M.S. et al. <i>Nature</i> 314: 268-70, 1985. A hapten-specific chimaeric IgE antibody with human physiological effector function.
	D215	Nielsen B. et al. <i>Eur. J. Haematol.</i> 48(3): 146-51, 1992. Interferon- α -induced changes in surface antigens in a hairy-cell leukemia (JOK-1), and a Burkitt's lymphoma cell line (Daudi) during <i>in vitro</i> culture.
	D216	Non-Hodgkin's Lymphoma Pathologic Classification Project. <i>Cancer</i> 49(10): 2112-35, 1982. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas.
	D217	Oettgen H.C. et al. <i>Hybridoma</i> 2(1): 17-28, 1983. Further biochemical studies of the human B-cell differentiation antigens B1 and B2.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 15 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D218	Oncology Nursing Society. onsopcontent.ons.org/oes/online_cc/lymph/.05-classification.htm , retrieved 25 February 2003. Current therapies and future directions in the treatment of non-Hodgkin's lymphoma.
	D219	Ozato K. et al. <i>J. Immunol.</i> 126(1): 317-21, 1981. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.
	D220	Parker B.A. et al. <i>Cancer Res.</i> 50(3): 1022s-1028s, 1990. Radioimmunotherapy of human B-cell lymphoma with ⁹⁰ Y-conjugated antiidiotype monoclonal antibody.
	D221	Pearson J.W. et al. <i>Cancer Res.</i> 49(18): 4990-95, 1989. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
	D222	Petryk M. et al. <i>Oncologist</i> 6: 317-26, 2001. ASCO 2001: Critical commentaries: Hematologic malignancies.
	D223	Pietersz G.A. et al. <i>Immunol. Cell. Biol.</i> 65(2): 111-25, 1987. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.
	D224	Piro L.D. et al. <i>Ann. Oncol.</i> 10: 655-61, 1999. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
	D225	Polyak M.J. et al. <i>Blood</i> 99: 3256-62, 2002. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.
	D226	Press O. et al. <i>Proc. Ann. Mtg. ASCO</i> 5: 221, abst. no. 864, 1986. Serotherapy of malignant B cell lymphomas with monoclonal antibody 1F5 (anti-CD20).
	D227	Press O.W. <i>Cancer J. Sci. Amer.</i> 4(Suppl 2): S19-S26, Jul. 1998. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
	D228	Press O.W. et al. <i>Adv. Exp. Med. Biol.</i> 303: 91-96, 1991. Radiolabeled antibody therapy of human b cell lymphomas.
	D229	Press O.W. et al. <i>Blood</i> 69(2): 584-91, 1987. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.
	D230	Press O.W. et al. <i>Cancer Res.</i> 49(17): 4906-12, 1989. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 16 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D231	Press O.W. et al. <i>J. Clin. Oncol.</i> 7(8): 1027-38, 1989. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
	D232	Press O.W. et al. <i>Lancet</i> 346(8971): 336-40, 1995. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.
	D233	Press O.W. et al. <i>N. Engl. J. Med.</i> 329(17): 1219-23, 1993. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
	D234	Press O.W. et al. <i>Proc. Ann. Mtg. ASCO</i> 17, abst. no. 9, May 1998. A phase I/II trial of high dose iodine-131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas.
	D235	Reff M. et al. <i>J. Cell. Biochem. Suppl.</i> 17E: 260, abst. no. T103, 1993. Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20.
	D236	Reff M.E. et al. <i>Blood</i> 83(2): 435-45, 1994. Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20.
	D237	Reilly R.M. <i>Clin. Pharm.</i> 10: 359-75, 1991. Radioimmunotherapy of malignancies.
	D238	Rottenburger C. et al. <i>Br. J. Haematol.</i> 106(2): 545-52, 1999. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation.
	D239	Sahagan B.G. et al. <i>J. Immunol.</i> 137: 1066-74, 1986. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.
	D240	Scharff M. <i>Harvey Lectures</i> 69: 125-42, 1974. The synthesis, assembly, and secretion of immunoglobulin: a biochemical and genetic approach.
	D241	Schlom J. et al. <i>J. Natl. Cancer Inst.</i> 82(9): 763-71, 1990. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.
	D242	Schwartz-Albiez R. et al. <i>J. Immunol.</i> 140(3): 905-14, 1988. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein.
	D243	See-Lasley K. et al. <i>Manual of Oncology Therapeutics</i> . St. Louis: C.V. Mosby Co., pages 44-71, 1981. Hodgkin's disease and non-Hodgkin's lymphoma.
	D244	Senter P.D. <i>FASEB J.</i> 4: 188-93, 1990. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
	D245	Senter P.D. et al. <i>Adv. Exp. Med. Biol.</i> 303: 97-105, 1991. Activation of prodrugs by antibody-enzyme conjugates.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 17 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D246	Senter P.D. et al. <i>Cancer Res.</i> 49: 5789-92, 1989. Enhancement of the <i>in vitro</i> and <i>in vivo</i> antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
	D247	Shan D. et al. <i>Clin. Cancer Res.</i> 7(8): 2490-95, 2001. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
	D248	Sharkey R.M. et al. <i>Cancer Res.</i> 50(3): 964s-969s, 1990. Biological considerations for radioimmunotherapy.
	D249	Shulman M. et al. <i>Nature</i> 276(5685): 269-72, 1978. A better cell line for making hybridomas secreting specific antibodies.
	D250	Smalley R.V. et al. <i>N. Engl. J. Med.</i> 327(19): 1336-41, 1992. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
	D251	Smeland E.B. et al. <i>J. Immunol.</i> 138(10): 3179-84, 1987. Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells.
	D252	Soiffer R.J. et al. <i>Blood</i> 79(2): 517-26, 1992. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
	D253	Soiffer R.J. et al. <i>Blood</i> 84(3): 964-971, 1994. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
	D254	Solal-Celigny P. et al. <i>J. Clin. Oncol.</i> 16(7): 2332-38, 1998. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
	D255	Srivastava S.C. et al. <i>Nucl. Med. Biol. (I.J. Rad. Appl. Instrum. B)</i> 18(6): 589-603, 1991. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies.
	D256	Stashenko P. et al. <i>J. Immunol.</i> 125(4): 1678-85, 1980. Characterization of Human B Lymphocyte-Specific Antigen.
	D257	Staudt L.M. et al. Manuscript from pubmedcentral at NIH, edited paper published at <i>Adv. Immunol.</i> 87: 163-208, 2005. The biology of human lymphoid malignancies revealed by gene expression profiling.
	D258	Stewart J.S.W. et al. <i>Int. J. Cancer Suppl.</i> 3: 71-76, 1988. Intraperitoneal ¹³¹ I- And ⁹⁰ Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D259	Sun L.K. et al. <i>Hybridoma</i> 5(Suppl. 1): S17-20, 1986. Chimeric antibodies with 17-1A-derived variable and human constant regions.
	D260	Tan L.K. et al. <i>J. Immunol.</i> 135: 3564-67, 1985. A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells.
	D261	Tedder T.F. et al. <i>Eur J. Immunol.</i> 16(8): 881-87, 1986. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes.
	D262	Tedder T.F. et al. <i>J. Immunol.</i> 135(2): 973-79, 1985. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
	D263	Tedder T.F. et al. <i>J. Immunol.</i> 141(12): 4388-94, 1988. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19.
	D264	Teeling J.L. et al. <i>Blood</i> 104:1793-1800, 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
	D265	Teeling J.L. et al. <i>J. Immunol.</i> 277: 362-71, 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
	D266	Tobinai K. et al. <i>Ann. Oncol.</i> 9(5): 527-34, 1998. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
	D267	Tsai D.E. et al. <i>Blood</i> 92(10 Suppl. 1): 415a, abst. no. 1713, Nov. 1998. Progressive intermediate grade non-Hodgkin's lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCt) has a high response rate to rituximab.
	D268	Tsai D.E. et al. <i>Bone Marrow Transplant.</i> 24(5): 521-26, 1999. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
	D269	Tsai D.E. et al. <i>Clin. Lymphoma Myeloma</i> 1(1): 62-66, 2000. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy.
	D270	Uckun F.M. et al. <i>Cancer Res.</i> 45(1): 69-75, 1985. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.
	D271	Uckun F.M. et al. <i>J. Immunol.</i> 134(5): 3504-15, 1985. Combined <i>ex vivo</i> treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 19 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D272	Urlaub, G. et al. <i>Som. Cell. Mol. Genet.</i> 12(6): 555-66, 1986. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions.
	D273	Valentine M.A. et al. <i>J. Biol. Chem.</i> 264: 11282-87, 1989. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.
	D274	van der Kolk L.E. et al. <i>Blood</i> 92(10 Suppl. 1): 241b, abst. no. 4037, Nov. 1998. Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: a phase I/II clinical trial.
	D275	van der Kolk L.E. et al. <i>Br. J. Haematol.</i> 102(1): 243, abst. no. P-0970, Jul. 1998. Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: a phase I/II clinical trial.
	D276	Venugopal P. et al. <i>Blood</i> 92(10 Suppl. 1): 247a, abst. no. 1009, Nov. 1998. Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines.
	D277	Verkh L.I. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: abst. no. 154, 1998. Dosimetry results of ONCOLYM™ in the treatment of refractory B cell non-Hodgkin's lymphoma (NHL).
	D278	Vey N. et al. <i>Leuk. Lymphoma</i> 22(1-2): 107-14, 1996. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas.
	D279	Vose J.M. et al. <i>J. Clin. Oncol.</i> 19(2): 389-97, 2001. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
	D280	Wadler S. et al. <i>Semin. Oncol.</i> 19(2 Suppl. 3): 45-48, 1992. Principles in the biomodulation of cytotoxic drugs by interferons.
	D281	Wahl R.L. et al. <i>Proc. Ann. Mtg. ASCO</i> 17: 40a, abst. no. 156, May 1998. Successful re-treatment of non-Hodgkin's lymphoma (NHL) with iodine-131 anti-B1 antibody.
	D282	Welte K. et al. <i>Blood</i> 64: 380-85, 1984. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2.
	D283	Wessels B.W. et al. <i>Med. Phys.</i> 11(5): 638-45, 1984. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
	D284	White C.A. et al. <i>Ann. Oncol.</i> 10(3 Suppl): 64, abst. no. 215, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDEC-Y2B8 phase I/II ⁹⁰ yttrium trial.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 20 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D285	White C.A. et al. <i>Ann. Rev. Med.</i> 52: 125-45, 2001. Antibody-targeted immunotherapy for treatment of malignancy.
	D286	White C.A. et al. <i>Blood</i> 87(9): 3640-49, 1996. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotypic monoclonal antibodies.
	D287	White C.A. et al. <i>Eur. J. Cancer</i> 35: S57, abst. no. 107, 1999. Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma.
	D288	Winkler U. et al. <i>Blood</i> 92(10 Suppl. 1): 285b, abst. no. 4228, Nov. 1998. Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
	D289	Wiseman G. et al. <i>Blood</i> 92(10 Suppl. 1): 417a, abst. no. 1721, Nov. 1998. IDEC-Y2B8 radioimmunotherapy: baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry.
	D290	Wiseman G. et al. <i>Cancer Biother. Radiopharm.</i> 13(1): 59, abst. no. 22, 1998. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 ⁹⁰ yttrium anti-CD20 monoclonal antibody.
	D291	Wiseman G. et al. <i>Cancer Biother. Radiopharm.</i> 13(4): 317, abst. no. 51, 1998. IDEC-Y2B8 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim analysis.
	D292	Wiseman G. et al. <i>Cancer Biother. Radiopharm.</i> 14(4): 315, abst. no. 2, 1999. ⁹⁰ Yttrium labelled IDEC Y2B8 anti-CD20 radioimmunotherapy.
	D293	Wiseman G. et al. <i>I.J. Rad. Oncol. Biol. Phys.</i> 45(10 Suppl): 390, abst. no. 260, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's Lymphoma (NHL) with IDEC-Y2B8.
	D294	Wiseman G. et al. <i>Proc. Ann. Mtg. ASCO</i> 17, 1998. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 ⁹⁰ yttrium radioimmunotherapy.
	D295	Wiseman G.A. et al. <i>Blood</i> 92(10 Suppl. 1): 510a, abst. no. 2273, Nov. 1998. IDEC-Y2B8 (⁹⁰ Y conjugated anti-CD20) dosimetry calculated from ¹¹¹ In anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM).
	D296	Wiseman G.A. et al. <i>Blood</i> 94(10 Suppl. 1): 92a, abst. no. 403, 1999. ZEVALIN™ biodistribution and dosimetry estimated normal organ absorbed radiation doses are not affected by prior therapy with rituximab.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 21 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D297	Wiseman G.A. <i>et al.</i> <i>Clin. Cancer Res.</i> 5(Suppl.): 3281s-3286s, 1999. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a ⁹⁰ Y-labeled anti-CD20 monoclonal antibody.
	D298	Wiseman G.A. <i>et al.</i> <i>I.J. Oncol. Biol. Phys.</i> 42(1 Suppl.): 130, abst. no. 11, 1998. IDEC-Y2B8 (⁹⁰ yttrium ibritumomab tiuxetan) radioimmunotherapy safety results in relapsed or chemotherapy refractory non-Hodgkin's lymphoma patients treated at reduced doses because of pre-existing thrombocytopenia.
	D299	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 38(5 Suppl.): 251, abst. no. 1062, 1997. Y-90 anti-CD20 monoclonal antibody (IDEC-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma.
	D300	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 39(5 Suppl.): 185P, abst. no. 836, 1998. Whole-body gamma camera image quantification from multiple camera types for radioisotope therapy dosimetry.
	D301	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 39(5 Suppl.): 69P, abst. no. 267, 1998. Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDEC-Y2B8 yttrium-90 anti-CD20 monoclonal antibody.
	D302	Wiseman G.A. <i>et al.</i> <i>J. Nucl. Med.</i> 40(1 Suppl.): 64P, abst. no. 260, 1999. Final dosimetry results of IDEC-Y2B8 phase I/II ⁹⁰ yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL).
	D303	Wiseman G.A. <i>et al.</i> <i>Proc. Ann. Mtg. ASCO</i> 18: 4a, abst. no. 13, 1999. Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than normal organs.
	D304	Witherspoon R.P. <i>et al.</i> <i>Semin. Hematol.</i> 21(1): 2-10, 1984. Immunologic reconstitution after human marrow grafting.
	D305	Witzig T. <i>et al.</i> <i>Blood</i> 90(10 Suppl. 1): 586a, abst. no. 2606, 1997. IDEC-Y2B8 ⁹⁰ yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a phase I/II trial.
	D306	Witzig T. <i>et al.</i> <i>Blood</i> 92(10 Suppl. 1): 417a, abst. no. 1722, Nov. 1998. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly.
	D307	Witzig T.E. <i>et al.</i> <i>Blood</i> 94(10 Suppl. 1): 92a, abst. no. 400, 1999. Reduced-dose ZEVALIN TM radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of interim results of a phase II trial.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 22 OF 23	

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01201	Serial No:	09/ 436,347
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	9 November 1999	Art Unit:	1643

INITIAL	INDEX	CITATION
	D308	Witzig T.E. et al. <i>J. Clin. Oncol.</i> 17(12): 3793-3803, 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
	D309	Witzig T.E. et al. <i>J. Clin. Oncol.</i> 20: 2453-63, 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
	D310	Witzig T.E. et al. <i>J. Clin. Oncol.</i> 20(15): 3262-69, 2002. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
	D311	Witzig T.E. et al. <i>J. Immunother.</i> 21(6): 463, abst. no. 2805, 1998. IDEC-Y2B8 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma.
	D312	Witzig T.E. et al. <i>Proc. Ann. Mtg. ASCO</i> 18: 41a, abst. no. 152, 1999. Commonly used response criteria for non-Hodgkin's lymphoma (NHL) applied to IDEC-Y2B8 radioimmunotherapy trial: importance of "normal" lymph node size.
	D313	Witzig T.E. et al. <i>Blood</i> 94(10 Suppl. 1): 631a, abst. no. 2805, 1999. Prospective randomized controlled study of ZEVALIN™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results.
	D314	Yang H. et al. <i>Am. J. Hematol.</i> 62: 247-50, 1999. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
	D315	Yokota S. et al. <i>Cancer Res.</i> 50: 32-37, 1990. Synergistic potentiation of <i>in vivo</i> antitumor activity of anti-human T-leukemia immunotoxins by recombinant α -interferon and daunorubicin.

EXAMINER	DATE CONSIDERED
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	
SHEET 23 OF 23	